130 research outputs found
UTMOST, a single and cross-tissue TWAS (Transcriptome Wide Association Study), reveals new ASD (Autism Spectrum Disorder) associated genes
Autism spectrum disorders (ASD) is a complex neurodevelopmental disorder that may significantly impact on the affected individual’s life. Common variation (SNPs) could explain about 50% of ASD heritability. Despite this fact and the large size of the last GWAS meta-analysis, it is believed that hundreds of risk genes in ASD have yet to be discovered. New tools, such as TWAS (Transcriptome Wide Association Studies) which integrate tissue expression and genetic data, are a great approach to identify new ASD susceptibility genes. The main goal of this study is to use UTMOST with the publicly available summary statistics from the largest ASD GWAS meta-analysis as genetic input. In addition, an in silico biological characterization for the novel associated loci was performed. Our results have shown the association of 4 genes at the brain level (CIPC, PINX1, NKX2-2, and PTPRE) and have highlighted the association of NKX2-2, MANBA, ERI1, and MITF at the gastrointestinal level. The gastrointestinal associations are quite relevant given the well-established but unexplored relationship between ASD and gastrointestinal symptoms. Cross-tissue analysis has shown the association of NKX2-2 and BLK. UTMOST-associated genes together with their in silico biological characterization seems to point to different biological mechanisms underlying ASD etiology. Thus, it would not be restricted to brain tissue and it will involve the participation of other body tissues such as the gastrointestinalS
De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD): Pathway and Network Analysis
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder (NDD) defined by impairments in social communication and social interactions, accompanied by repetitive behavior and restricted interests. ASD is characterized by its clinical and etiological heterogeneity, which makes it difficult to elucidate the neurobiological mechanisms underlying its pathogenesis. Recently, de novo mutations (DNMs) have been recognized as strong source of genetic causality. Here, we review different aspects of the DNMs associated with ASD, including their functional annotation and classification. In addition, we also focus on the most recent advances in this area, such as the detection of PZMs (post-zygotic mutations), and we outline the main bioinformatics tools commonly employed to study these. Some of these approaches available allow DNMs to be analyzed in the context of gene networks and pathways, helping to shed light on the biological processes underlying ASD. To end this review, a brief insight into the future perspectives for genetic studies into ASD will be providedAA-G was supported by Fundación María José Jove. CR-F was supported by a contract from the ISCIII and FEDERS
The non-coding genome in Autism Spectrum Disorders
Autism Spectrum Disorders (ASD) are a group of neurodevelopmental disorders (NDDs) characterized by difficulties in social interaction and communication, repetitive behavior, and restricted interests. While ASD have been proven to have a strong genetic component, current research largely focuses on coding regions of the genome. However, non-coding DNA, which makes up for ∼99% of the human genome, has recently been recognized as an important contributor to the high heritability of ASD, and novel sequencing technologies have been a milestone in opening up new directions for the study of the gene regulatory networks embedded within the non-coding regions. Here, we summarize current progress on the contribution of non-coding alterations to the pathogenesis of ASD and provide an overview of existing methods allowing for the study of their functional relevance, discussing potential ways of unraveling ASD's “missing heritability”S
Novel Gene-Based Analysis of ASD GWAS: Insight Into the Biological Role of Associated Genes
Autism spectrum disorder (ASD) is a neurodevelopmental disorder
characterized by its significant social impact and high heritability. The latest meta-analysis
of ASD GWAS (genome-wide association studies) has revealed the association of several
SNPs that were replicated in additional sets of independent samples. However, summary
statistics from GWAS can be used to perform a gene-based analysis (GBA). GBA allows
to combine all genetic information across the gene to create a single statistic (p-value
for each gene). Thus, PASCAL (Pathway scoring algorithm), a novel GBA tool, has been
applied to the summary statistics from the latest meta-analysis of ASD. GBA approach
(testing the gene as a unit) provides an advantage to perform an accurate insight into
the biological ASD mechanisms. Therefore, a gene-network analysis and an enrichment
analysis for KEGG and GO terms were carried out. GENE2FUNC was used to create gene
expression heatmaps and to carry out differential expression analysis (DEA) across GTEx
v7 tissues and Brainspan data. dbMDEGA was employed to perform a DEG analysis
between ASD and brain control samples for the associated genes and interactors.AA-G was supported by Fundación María José Jove. CR-F was supported by a contract from the ISCIII and FEDERS
The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
In recent decades, survival rates in colorectal cancer have improved greatly due to pharmacological treatment. However, many patients end up developing adverse drug reactions that can be severe or even life threatening, and that affect their quality of life. These remain a limitation, as they may force dose reduction or treatment discontinuation, diminishing treatment efficacy. From candidate gene approaches to genome-wide analysis, pharmacogenomic knowledge has advanced greatly, yet there is still huge and unexploited potential in the use of novel technologies such as next-generation sequencing strategies. This review summarises the road of colorectal cancer pharmacogenomics so far, presents considerations and directions to be taken for further works and discusses the path towards implementation into clinical practiceThis research was supported by grant FIS PI 16/01057- ISCIII (to Á.C.), ISCIII PFIS grant FI17/00215 (to A.R.S.) and Fundación Olga Torres (to C.F.-R.)S
SPSmart: adapting population based SNP genotype databases for fast and comprehensive web access
Background: In the last five years large online resources of human variability have appeared,
notably HapMap, Perlegen and the CEPH foundation. These databases of genotypes with population
information act as catalogues of human diversity, and are widely used as reference sources for
population genetics studies. Although many useful conclusions may be extracted by querying
databases individually, the lack of flexibility for combining data from within and between each
database does not allow the calculation of key population variability statistics.
Results: We have developed a novel tool for accessing and combining large-scale genomic
databases of single nucleotide polymorphisms (SNPs) in widespread use in human population
genetics: SPSmart (SNPs for Population Studies). A fast pipeline creates and maintains a data mart
from the most commonly accessed databases of genotypes containing population information: data
is mined, summarized into the standard statistical reference indices, and stored into a relational
database that currently handles as many as 4 × 109 genotypes and that can be easily extended to
new database initiatives. We have also built a web interface to the data mart that allows the
browsing of underlying data indexed by population and the combining of populations, allowing
intuitive and straightforward comparison of population groups. All the information served is
optimized for web display, and most of the computations are already pre-processed in the data
mart to speed up the data browsing and any computational treatment requested.
Conclusion: In practice, SPSmart allows populations to be combined into user-defined groups,
while multiple databases can be accessed and compared in a few simple steps from a single query.
It performs the queries rapidly and gives straightforward graphical summaries of SNP population
variability through visual inspection of allele frequencies outlined in standard pie-chart format. In
addition, full numerical description of the data is output in statistical results panels that include
common population genetics metrics such as heterozygosity, Fst and In.The grants from the Xunta de Galicia (PGIDIT06PXIB208079PR) and Fundación de Investigación Médica Mutua Madrileña awarded to AS partially
supported this projectS
Experimental Models to Study Autism Spectrum Disorders: hiPSCs, Rodents and Zebrafish
Autism Spectrum Disorders (ASD) affect around 1.5% of the global population, which manifest alterations in communication and socialization, as well as repetitive behaviors or restricted interests. ASD is a complex disorder with known environmental and genetic contributors; however, ASD etiology is far from being clear. In the past decades, many efforts have been put into developing new models to study ASD, both in vitro and in vivo. These models have a lot of potential to help to validate some of the previously associated risk factors to the development of the disorder, and to test new potential therapies that help to alleviate ASD symptoms. The present review is focused on the recent advances towards the generation of models for the study of ASD, which would be a useful tool to decipher the bases of the disorder, as well as to conduct drug screenings that hopefully lead to the identification of useful compounds to help patients deal with the symptoms of ASDConsellería de Educación, Universidade e Formación Profesional (ED431C 2018/28)//FIS PI19/00809 ISCIII//Xunta de Galicia (Centro singular de investigación de Galicia acreditación 2019–2022) and the European Union (European Regional Development Fund - ERDF) (ED431G 2019/02)S
Patterns of genetic differentiation and the footprints of historical migrations in the Iberian Peninsula
The Iberian Peninsula is linguistically diverse and has a complex demographic history, including a centuries-long period of Muslim rule. Here, we study the fine-scale genetic structure of its population, and the genetic impacts of historical events, leveraging powerful, haplotype-based statistical methods to analyse 1413 individuals from across Spain. We detect extensive fine-scale population structure at extremely fine scales (below 10 Km) in some regions, including Galicia. We identify a major east-west axis of genetic differentiation, and evidence of historical north to south population movement. We find regionally varying fractions of north-west African ancestry (0–11%) in modern-day Iberians, related to an admixture event involving European-like and north-west African-like source populations. We date this event to 860–1120 CE, implying greater genetic impacts in the early half of Muslim rule in Iberia. Together, our results indicate clear genetic impacts of population movements associated with both the Muslim conquest and the subsequent Reconquista.We acknowledge support from the Wellcome Trust (203141/Z/16/Z, 090532/Z/09/Z,
098387/Z/12/Z, 095552/Z/11/Z, 212284/Z/18/Z) and Fondo de Investigación Sanitaria
(Grants PI13/01136 and PI16/01057)S
FAS system deregulation in T-cell lymphoblastic lymphoma
The acquisition of resistance towards FAS-mediated apoptosis may be required for tumor formation. Tumors from various
histological origins exhibit FAS mutations, the most frequent being hematological malignancies. However, data regarding FAS
mutations or FAS signaling alterations are still lacking in precursor T-cell lymphoblastic lymphomas (T-LBLs). The available data
on acute lymphoblastic leukemia, of precursor origin as well, indicate a low frequency of FAS mutations but often report a
serious reduction in FAS-mediated apoptosis as well as chemoresistance, thus suggesting the occurrence of mechanisms able
to deregulate the FAS signaling pathway, different from FAS mutation. Our aim at this study was to determine whether
FAS-mediated apoptotic signaling is compromised in human T-LBL samples and the mechanisms involved. This study on 26
T-LBL samples confirms that the FAS system is impaired to a wide extent in these tumors, with 57.7% of the cases presenting any
alteration of the pathway. A variety of mechanisms seems to be involved in such alteration, in order of frequency the
downregulation of FAS, the deregulation of other members of the pathway and the occurrence of mutations at FAS. Considering
these results together, it seems plausible to think of a cumulative effect of several alterations in each T-LBL, which in turn may
result in FAS/FASLG system deregulation. Since defective FAS signaling may render the T-LBL tumor cells resistant to apoptotic
cell death, the correct prognosis, diagnosis and thus the success of anticancer therapy may require such an in-depth knowledge
of the complete scenario of FAS-signaling alterations.S
LIPG endothelial lipase and breast cancer risk by subtypes
Experimental data showed that endothelial lipase (LIPG) is a crucial player in breast cancer. However, very limited data exists on the role of LIPG on the risk of breast cancer in humans. We examined the LIPG-breast cancer association within our population-based case–control study from Galicia, Spain, BREOGAN (BREast Oncology GAlicia Network). Plasma LIPG and/or OxLDL were measured on 114 breast cancer cases and 82 controls from our case–control study, and were included in the present study. The risk of breast cancer increased with increasing levels of LIPG (multivariable OR for the highest category (95% CI) 2.52 (1.11–5.81), P-trend = 0.037). The LIPG-breast cancer association was restricted to Pre-menopausal breast cancer (Multivariable OR for the highest LIPG category (95% CI) 4.76 (0.94–28.77), P-trend = 0.06, and 1.79 (0.61–5.29), P-trend = 0.372, for Pre-menopausal and Post-menopausal breast cancer, respectively). The LIPG-breast cancer association was restricted to Luminal A breast cancers (Multivariable OR for the highest LIPG category (95% CI) 3.70 (1.42–10.16), P-trend = 0.015, and 2.05 (0.63–7.22), P-trend = 0.311, for Luminal A and non-Luminal A breast cancers, respectively). Subset analysis only based on HER2 receptor indicated that the LIPG-breast cancer relationship was restricted to HER2-negative breast cancers (Multivariable OR for the highest LIPG category (95% CI) 4.39 (1.70–12.03), P-trend = 0.012, and 1.10 (0.28–4.32), P-trend = 0.745, for HER2-negative and HER2-positive tumors, respectively). The LIPG-breast cancer association was restricted to women with high total cholesterol levels (Multivariable OR for the highest LIPG category (95% CI) 6.30 (2.13–20.05), P-trend = 0.018, and 0.65 (0.11–3.28), P-trend = 0.786, among women with high and low cholesterol levels, respectively). The LIPG-breast cancer association was also restricted to non-postpartum breast cancer (Multivariable OR for the highest LIPG category (95% CI) 3.83 (1.37–11.39), P-trend = 0.003, and 2.35 (0.16–63.65), P-trend = 0.396, for non-postpartum and postpartum breast cancer, respectively), although we lacked precision. The LIPG-breast cancer association was more pronounced among grades II and III than grade I breast cancers (Multivariable ORs for the highest category of LIPG (95% CI) 2.73 (1.02–7.69), P-trend = 0.057, and 1.90 (0.61–6.21), P-trend = 0.170, for grades II and III, and grade I breast cancers, respectively). No association was detected for OxLDL levels and breast cancer (Multivariable OR for the highest versus the lowest category (95% CI) 1.56 (0.56–4.32), P-trend = 0.457)The BREast Oncology GAlician Network (BREOGAN) is funded by FIS ISCIII/PI12/02125 and PI17/00918 Acción Estratégica de Salud del Instituto de Salud Carlos III / Cofinanciado FEDER; FIS Intrasalud PI13/01136; Programa Grupos Emergentes, Cancer Genetics Unit, CHUVI Vigo Hospital, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Consellería de Industria Programa Sectorial de Investigación Aplicada, PEME I+D e I+D Suma del Plan Gallego de Investigación, Desarrollo e Innovación Tecnológica de la Consellería de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigación Clínica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. MM funded by the Spanish Ministry of Science, Innovation and Universities under Grant RTI2018-099646-B-I00, the Consellerı́a de Educación, Universidade e Formación Profesional and the European Regional Development Fund under Grant ED431G-2019/04S
- …